SCNI - Scinai Immunotherapeutics to Attend BIO-Europe Munich 2023 | Benzinga
Showcasing Scinai's end-to-end cGMP Biologics CDMO services at booth 271
Pursuing partnerships for Scinai's pipeline of novel VHH antibody-based therapies
JERUSALEM, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via IBN -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) today announces that it will be showcasing both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline at BIO-Europe, one of Europe's premier pharmaceutical industry partnering events, taking place Nov. 6 to 8 in Munich, Germany.
Members of the company's executive leadership team will be available to meet with potential partners and clients of the company's end-to-end biologics CDMO services at Scinai's booth 271.
One-to-one meetings may be requested through the BIO partnering platform, accessible to participants after registration through https://informaconnect.com/bioeurope/. Interested parties are also welcome to contact Scinai directly through the information provided below.
Leveraging the company's state-of-the-art manufacturing facility for biopharmaceutical products, Scinai's CDMO offers biologic drugs process development and scale-up for protein-based drugs, analytical method development for QC testing and cGMP manufacturing including aseptic filling at FDA/EMA standards to pharmaceutical and biotech clients.
In parallel, Scinai's in-house R&D program is focused on developing, manufacturing and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. Development is currently centered on a